Advanced Proteome Therapeutics Corporation
APTCF · OTC
4/30/2023 | 1/31/2023 | 10/31/2022 | 7/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.11 | -0.02 | 0.14 |
| FCF Yield | -43.75% | -3.34% | -7.06% | -6.25% |
| EV / EBITDA | -1.08 | -11.68 | -14.64 | -30.72 |
| Quality | ||||
| ROIC | -1,654.63% | 38.71% | 48.19% | 51.15% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.34 | 0.36 | 0.98 | 1.90 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -487.79% | 51.95% | -13.08% | 2.64% |
| Safety | ||||
| Net Debt / EBITDA | 0.01 | -0.47 | -0.03 | 1.95 |
| Interest Coverage | -39.70 | -23.90 | -19.86 | -35.55 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -49.46 | -50.64 |
| Cash Conversion Cycle | -32,614.37 | -22,269.21 | -18,125.06 | -19,437.59 |